Monopar Therapeutics Inc (MNPR)

$0.6146

Market is closed - opens 7 PM, 23 May 2024

Insights on Monopar Therapeutics Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 58.5% return, outperforming this stock by 90.7%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 232.5% return, outperforming this stock by 321.8%

Performance

  • $0.61
    $0.64
    $0.61
    downward going graph

    0.0%

    Downside

    Day's Volatility :3.94%

    Upside

    3.94%

    downward going graph
  • $0.27
    $1.75
    $0.61
    downward going graph

    55.1%

    Downside

    52 Weeks Volatility :84.35%

    Upside

    65.14%

    downward going graph

Returns

PeriodMonopar Therapeutics IncIndex (Russel 2000)
3 Months
-45.44%
0.0%
6 Months
97.77%
0.0%
1 Year
-32.18%
0.0%
3 Years
-89.24%
-20.1%

Highlights

Market Capitalization
10.8M
Book Value
$0.43
Earnings Per Share (EPS)
-0.52
Wall Street Target Price
2.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-48.38%
Return On Equity TTM
-92.67%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
Diluted Eps TTM
-0.52
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.4
EPS Estimate Next Year
-0.31
EPS Estimate Current Quarter
-0.14
EPS Estimate Next Quarter
-0.09

Analyst Recommendation

Buy
    70%Buy
    30%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Monopar Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
10
Hold
3
3
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 225.41%

Current $0.61
Target $2.00

Technicals Summary

Sell

Neutral

Buy

Monopar Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Monopar Therapeutics Inc
Monopar Therapeutics Inc
-3.31%
97.77%
-32.18%
-89.24%
-97.69%
Moderna, Inc.
Moderna, Inc.
37.56%
83.82%
13.37%
-12.47%
553.14%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
10.42%
24.29%
32.26%
98.6%
210.52%
Novo Nordisk A/s
Novo Nordisk A/s
7.9%
30.89%
58.53%
230.87%
458.51%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
10.52%
25.13%
30.01%
109.26%
156.43%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Monopar Therapeutics Inc
Monopar Therapeutics Inc
NA
NA
NA
-0.4
-0.93
-0.48
NA
0.43
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.46
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.16
29.16
1.46
44.2
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.83
45.83
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.9
28.9
0.53
17.11
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Monopar Therapeutics Inc
Monopar Therapeutics Inc
Buy
$10.8M
-97.69%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$54.0B
553.14%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.8B
210.52%
29.16
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$592.1B
458.51%
45.83
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$115.1B
156.43%
28.9
39.46%

Institutional Holdings

  • Millennium Management LLC

    1.10%
  • Renaissance Technologies Corp

    0.28%
  • Vanguard Group Inc

    0.26%
  • Geode Capital Management, LLC

    0.24%
  • Gerber LLC

    0.16%
  • Virtu Financial LLC

    0.16%

Company Information

monopar therapeutics inc., a biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the united states. it is involved in developing validive, a clonidine mucobuccal tablet that is in phase iii for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin, a topoisomerase ii-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart; and mnpr-101, a humanized monoclonal antibody for treating advanced solid cancers. the company has a collaboration grupo espaã±ol de investigaciã³n en sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and northstar medical radioisotopes, llc to develop radio-immuno-therapeutics targeting severe covid-19. monopar therapeutics inc. was founded in 2014 and is headquartered in wilmette, illinois.

Organization
Monopar Therapeutics Inc
Employees
9
CEO
Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc
Industry
Health Technology

FAQs